Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jeffrey Ortstadt

Neurology Fort Myers, FL Medical Doctor

NPI 1467480376 CMS profile 433521

11215 Metro Pkwy Bldg 3, Fort Myers, FL 33966

Open in the dashboard

General payments

$7,862

473 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jeffrey Ortstadt of Fort Myers, FL is reported in the CMS Open Payments database as having received $7,862 across 473 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $78 4
2023 General $446 17
2022 General $591 20
2021 General $2,914 181
2020 General $1,783 116
2019 General $2,050 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Ortstadt
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jeffrey Ortstadt were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jeffrey Ortstadt Neurology median Middle half National median
2019 $2,050 $474 $118–$2,177 $163
2020 $1,783 $367 $82–$2,309 $114
2021 $2,914 $438 $104–$2,547 $132
2022 $591 $442 $103–$2,388 $149
2023 $446 $464 $119–$2,312 $160
2024 $78 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $847 48 payments
  2. Allergan Inc. $757 53 payments
  3. Novartis Pharmaceuticals Corporation $702 58 payments
  4. Amgen Inc. $481 34 payments
  5. Biogen, Inc. $379 21 payments
  6. Genzyme Corporation $333 16 payments
  7. Teva Pharmaceuticals USA, Inc. $311 27 payments
  8. EMD Serono, Inc. $281 12 payments
  9. UCB, Inc. $254 12 payments
  10. Alexion Pharmaceuticals, Inc. $249 8 payments
  11. Other $3,267 184 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $7,832 471 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23 1 payment
  3. Education $7 1 payment
Products named General payments · program years 2019–2024
  1. AIMOVIG $827 68 payments
  2. BOTOX $548 37 payments
  3. DUOPA $540 32 payments
  4. UBRELVY Neuroscience $251 13 payments
  5. Wakix $243 12 payments
  6. AUBAGIO $208 9 payments
  7. NURTEC ODT $199 20 payments
  8. GILENYA $179 10 payments
  9. UBRELVY Neuroscience $170 13 payments
  10. VUMERITY $162 9 payments
  11. Other $4,625 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$6,570

Medicare's payments for the services billed

Medicare patients

47

Average age 78

Services billed

47

22 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 53%
Diabetes 51%
Chronic kidney disease 51%
Heart failure 36%
Atrial fibrillation 34%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUOPA
  • AbbVie, Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record